Comments

Immuneering

IMRXNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$1.16
0.054.50%
Last update: 9:29 AM
15 minutes delayed
Immuneering (IMRX) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$41.00
Lowest Price Target1
$3.00
Consensus Price Target1
$17.90

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

Immuneering (NASDAQ:IMRX) Stock, Analyst Ratings, Price Targets, Forecasts

Immuneering Corp has a consensus price target of $17.9 based on the ratings of 13 analysts. The high is $41 issued by Piper Sandler on January 7, 2022. The low is $3 issued by Jefferies on March 15, 2024. The 3 most-recent analyst ratings were released by Needham, Needham, and Mizuho on May 8, 2024, April 12, 2024, and April 2, 2024, respectively. With an average price target of $12.67 between Needham, Needham, and Mizuho, there's an implied 964.43% upside for Immuneering Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Feb
1
2
Mar
0
0
0
0
Apr
0
0
0
0
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.3
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Needham
Mizuho
Jefferies
Chardan Capital
Oppenheimer

1calculated from analyst ratings

Analyst Ratings for Immuneering

Buy NowGet Alert
05/08/2024Buy Now1160.5%Needham
Ami Fadia
 → $15ReiteratesBuy → BuyGet Alert
04/12/2024Buy Now1160.5%Needham
Ami Fadia
 → $15ReiteratesBuy → BuyGet Alert
04/02/2024Buy Now572.27%Mizuho
Graig Suvannavejh
$20 → $8MaintainsBuyGet Alert
03/15/2024Buy Now152.1%Jefferies
Michael Yee
$16 → $3DowngradeBuy → HoldGet Alert
03/15/2024Buy Now1244.54%Chardan Capital
Geulah Livshits
$21 → $16MaintainsBuyGet Alert
03/15/2024Buy Now1160.5%Needham
Ami Fadia
$20 → $15MaintainsBuyGet Alert
03/15/2024Buy Now—TD Cowen
Yaron Werber
—DowngradeOutperform → Market PerformGet Alert
03/14/2024Buy Now—Guggenheim
Michael Schmidt
—DowngradeBuy → NeutralGet Alert
03/11/2024Buy Now1580.67%Needham
Ami Fadia
 → $20ReiteratesBuy → BuyGet Alert
03/05/2024Buy Now2000.84%Oppenheimer
Jay Olson
$25 → $25ReiteratesOutperform → OutperformGet Alert
03/04/2024Buy Now1580.67%Needham
Ami Fadia
 → $20ReiteratesBuy → BuyGet Alert
02/01/2024Buy Now1580.67%Needham
Ami Fadia
 → $20ReiteratesBuy → BuyGet Alert
12/01/2023Buy Now1580.67%Needham
Ami Fadia
 → $20Initiates → BuyGet Alert
08/08/2023Buy Now2000.84%Oppenheimer
Mark Breidenbach
 → $25ReiteratesOutperform → OutperformGet Alert
08/07/2023Buy Now1748.74%Chardan Capital
Geulah Livshits
 → $22ReiteratesBuy → BuyGet Alert
08/04/2023Buy Now1076.47%Morgan Stanley
Jeffrey Hung
$14 → $14MaintainsEqual-WeightGet Alert
06/26/2023Buy Now2000.84%Oppenheimer
Mark Breidenbach
 → $25Assumes → OutperformGet Alert
04/19/2023Buy Now1076.47%Morgan Stanley
Jeffrey Hung
$5 → $14UpgradeUnderweight → Equal-WeightGet Alert
04/19/2023Buy Now1580.67%Mizuho
Mara Goldstein
$10 → $20UpgradeNeutral → BuyGet Alert
04/19/2023Buy Now1748.74%Chardan Capital
Geulah Livshits
$18 → $22MaintainsBuyGet Alert
04/18/2023Buy Now1748.74%Chardan Capital
Geulah Livshits
$18 → $22MaintainsBuyGet Alert
03/30/2023Buy Now740.34%Mizuho
Mara Goldstein
 → $10Initiates → NeutralGet Alert
03/07/2023Buy Now1412.61%Chardan Capital
Geulah Livshits
 → $18Reiterates → BuyGet Alert
02/03/2023Buy Now320.17%Morgan Stanley
Jeffrey Hung
$12 → $5DowngradeEqual-Weight → UnderweightGet Alert
07/15/2022Buy Now908.4%Morgan Stanley
David Lebowitz
$18 → $12MaintainsEqual-WeightGet Alert
07/08/2022Buy Now1412.61%Chardan Capital
Geulah Livshits
 → $18Initiates → BuyGet Alert
04/01/2022Buy Now2000.84%Oppenheimer
Mark Breidenbach
 → $25Initiates → OutperformGet Alert
01/07/2022Buy Now3345.38%Piper Sandler
Swapnil Malekar
 → $41Initiates → OverweightGet Alert
08/24/2021Buy Now—Cowen & Co.
Yaron Werber
—Initiates → OutperformGet Alert
08/24/2021Buy Now3429.41%Guggenheim
Michael Schmidt
—Initiates → BuyGet Alert
08/24/2021Buy Now3177.31%Morgan Stanley
David Lebowitz
—Initiates → Equal-WeightGet Alert
08/24/2021Buy Now4101.68%Jefferies
Michael Yee
—Initiates → BuyGet Alert

FAQ

Q

What is the target price for Immuneering (IMRX) stock?

A

The latest price target for Immuneering (NASDAQ:IMRX) was reported by Needham on May 8, 2024. The analyst firm set a price target for $15.00 expecting IMRX to rise to within 12 months (a possible 1193.10% upside). 16 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Immuneering (IMRX)?

A

The latest analyst rating for Immuneering (NASDAQ:IMRX) was provided by Needham, and Immuneering reiterated their buy rating.

Q

When was the last upgrade for Immuneering (IMRX)?

A

The last upgrade for Immuneering Corp happened on April 19, 2023 when Morgan Stanley raised their price target to $14. Morgan Stanley previously had an underweight for Immuneering Corp.

Q

When was the last downgrade for Immuneering (IMRX)?

A

The last downgrade for Immuneering Corp happened on March 15, 2024 when Jefferies changed their price target from $16 to $3 for Immuneering Corp.

Q

When is the next analyst rating going to be posted or updated for Immuneering (IMRX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immuneering, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immuneering was filed on May 8, 2024 so you should expect the next rating to be made available sometime around May 8, 2025.

Q

Is the Analyst Rating Immuneering (IMRX) correct?

A

While ratings are subjective and will change, the latest Immuneering (IMRX) rating was a reiterated with a price target of $15.00 to $15.00. The current price Immuneering (IMRX) is trading at is $1.16, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch